Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
LRP8 is a receptor for tick-borne encephalitis virus
Department of Microbiology and Immunology, Albert Einstein College of Medicine, NY, New York, United States.
Department of Microbiology and Immunology, Albert Einstein College of Medicine, NY, New York, United States.
Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
United States Army Medical Research Institute of Infectious Diseases, MD, Fort Detrick, United States; The Geneva Foundation, WA, Tacoma, United States; The Henry M. Jackson Foundation, MD, Bethesda, United States.
Visa övriga samt affilieringar
2025 (Engelska)Ingår i: Nature, ISSN 0028-0836, E-ISSN 1476-4687Artikel i tidskrift (Refereegranskat) Epub ahead of print
Abstract [en]

Tick-borne encephalitis virus (TBEV) causes tick-borne encephalitis (TBE), a severe and sometimes life-threatening disease characterized by viral invasion of the central nervous system with symptoms of neuroinflammation1,2. As with other orthoflaviviruses—enveloped, arthropod-borne RNA viruses—host factors required for TBEV entry remain poorly defined. Here we used a genome-scale CRISPR–Cas9-based screen to identify LRP8, an apolipoprotein E and reelin receptor with high expression in the brain, as a TBEV receptor. LRP8 downregulation reduced TBEV infection in human cells, and its overexpression enhanced infection. LRP8 bound directly to the TBEV E glycoprotein and mediated viral attachment and internalization into cells. An LRP8-based soluble decoy blocked infection of human cell lines and neuronal cells and protected mice from lethal TBEV challenge. LRP8’s role as a TBEV receptor has implications for TBEV neuropathogenesis and the development of antiviral countermeasures.

Ort, förlag, år, upplaga, sidor
Springer Nature, 2025.
Nationell ämneskategori
Infektionsmedicin Mikrobiologi inom det medicinska området
Identifikatorer
URN: urn:nbn:se:umu:diva-244874DOI: 10.1038/s41586-025-09500-2Scopus ID: 2-s2.0-105016879708OAI: oai:DiVA.org:umu-244874DiVA, id: diva2:2002830
Forskningsfinansiär
NIH (National Institutes of Health), R01AI132633; R01AI165932; R01AI174584; R21AI182834Marianne och Marcus Wallenbergs StiftelseRegion StockholmVetenskapsrådet, 2020-06249Vetenskapsrådet, 2021-06602Vetenskapsrådet, 2020-06224Karolinska InstitutetTillgänglig från: 2025-10-02 Skapad: 2025-10-02 Senast uppdaterad: 2025-10-02

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextScopus

Person

Rosendal, EbbaÖverby, Anna K.

Sök vidare i DiVA

Av författaren/redaktören
Rosendal, EbbaÖverby, Anna K.
Av organisationen
Molekylär Infektionsmedicin, Sverige (MIMS)Institutionen för klinisk mikrobiologi
I samma tidskrift
Nature
InfektionsmedicinMikrobiologi inom det medicinska området

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 41 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf